Prior COVID-19 infection significantly increased the 24-month risk of major adverse cardiovascular events (HR 2.78) compared to no prior infection in patients with ST-segment elevation myocardial infarction.
Cohort (n=200)
No
Does a history of COVID-19 infection increase the risk of major adverse cardiovascular events in STEMI patients undergoing reperfusion therapy?
A history of COVID-19 infection is an independent predictor of adverse long-term cardiovascular outcomes in STEMI patients, with primary PCI providing a better prognosis than thrombolytic therapy in this population.
Effect estimate: HR 2.78 (95% CI 1.45-5.33)
Absolute Event Rate: 31.4% vs 13%
p-value: p=<0.001
THE IMPACT OF COVID-19 INFECTION ON THE EFFICACY AND SAFETY OF REPERFUSION THERAPY IN ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION: SHORT- AND LONG-TERM OUTCOMES - научно-практическая статья медицинского журнала Узбекистана о достижениях в здравоохранении, эпидемиологии, санитарии и фармацевтике, а также о пропаганде ЗОЖ.
Fozilov et al. (Thu,) conducted a cohort in ST-segment elevation acute coronary syndrome (STEMI) (n=200). Prior COVID-19 infection vs. No prior COVID-19 infection was evaluated on Major adverse cardiovascular events (MACE) at 24 months (HR 2.78, 95% CI 1.45-5.33, p=<0.001). Prior COVID-19 infection significantly increased the 24-month risk of major adverse cardiovascular events (HR 2.78) compared to no prior infection in patients with ST-segment elevation myocardial infarction.